Clinical Trial

Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Record status
This record was last updated September 9, 2020 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
This study suggests that R-IDARAM combined with intrathecal immunochemotherapy may be high effective in elderly patients with primary central nervous system lymphoma (PCNSL).
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2016-07-14; most recent amendment 2020-09-08.
Trial Details
NCT Number NCT02836158
Lead Sponsor Navy General Hospital, Beijing
Conditions Primary Central Nervous System Lymphoma
Enrollment 100 participants
Start Date 2010-09
Primary Completion 2025-12 (estimated)
Study Completion 2030-12 (estimated)
Updated on ClinicalTrials.gov 2020-09-09